Abstract
Hepatitis B virus (HBV) infection is a severe health problem all over the world. However, there is still no satisfactory anti-HBV therapeutic strategy. Currently, promising alternative approaches toward the control of HBV infection include the development of structurally novel and more potent inhibitors obtained from natural products and structural modifications of synthetic molecules as seen in many cases. In this review, we will focus our interest on representative naturally occurring and synthetic small molecule non-nucleoside inhibitors with high anti-HBV potency and potential for future therapeutic regimens to combat HBV infection.
Keywords: HBV, Inhibitor, Non-nucleoside inhibitor, Chemotherapeutics, Natural products, Synthetic molecules, Heterocyclic compounds
Mini-Reviews in Medicinal Chemistry
Title: Naturally Occurring and Synthetic Bioactive Molecules as Novel Non-Nucleoside HBV Inhibitors
Volume: 10 Issue: 2
Author(s): Peng Zhan, Xuemei Jiang and Xinyong Liu
Affiliation:
Keywords: HBV, Inhibitor, Non-nucleoside inhibitor, Chemotherapeutics, Natural products, Synthetic molecules, Heterocyclic compounds
Abstract: Hepatitis B virus (HBV) infection is a severe health problem all over the world. However, there is still no satisfactory anti-HBV therapeutic strategy. Currently, promising alternative approaches toward the control of HBV infection include the development of structurally novel and more potent inhibitors obtained from natural products and structural modifications of synthetic molecules as seen in many cases. In this review, we will focus our interest on representative naturally occurring and synthetic small molecule non-nucleoside inhibitors with high anti-HBV potency and potential for future therapeutic regimens to combat HBV infection.
Export Options
About this article
Cite this article as:
Zhan Peng, Jiang Xuemei and Liu Xinyong, Naturally Occurring and Synthetic Bioactive Molecules as Novel Non-Nucleoside HBV Inhibitors, Mini-Reviews in Medicinal Chemistry 2010; 10 (2) . https://dx.doi.org/10.2174/138955710791185118
DOI https://dx.doi.org/10.2174/138955710791185118 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stable Expression of the Sodium/Iodide Symporter (NIS) for anti-Cancer Gene Therapy of Glioma Cells Using a Third Generation Self-Inactivating Lentiviral Vector System in Combination with 211At
Current Radiopharmaceuticals High-Dose Linoleic Acid Activated JAK2-STAT3 Signaling Pathway Involved in Cytokine Production and Lipogenesis in Pancreatic Exocrine Cells
Current Molecular Medicine Pathways Related to the Anti-Cancer Effects of Metabolites Derived from Cerrado Biome Native Plants: An Update and Bioinformatics Analysis on Oral Squamous Cell Carcinoma
Protein & Peptide Letters Clinical Implications of Methotrexate Pharmacogenetics in Childhood Acute Lymphoblastic Leukaemia
Current Drug Metabolism SENP1 as A Biomarker for the Diagnosis of Cancer: Review of the Science and Published Patents
Recent Patents on Biomarkers New Framework for the Discovery of PRC2 Inhibitors: Epigenetic Drugs
Current Drug Targets Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals Heat Shock Protein 90 – a Potential Target in the Treatment of Human Acute Myelogenous Leukemia
Current Cancer Drug Targets Protein Kinase C ζ Drives Sphingomyelin Metabolism in the Nucleus During Cell Proliferation
Current Chemical Biology A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor
Current Cancer Drug Targets PI3K/Akt Signalling Pathway Specific Inhibitors: A Novel Strategy to Sensitize Cancer Cells to Anti-Cancer Drugs
Current Pharmaceutical Design Recent Evidence on the Role of Dietary PUFAs in Cancer Development and Prevention
Current Medicinal Chemistry Discovery of New Biomarkers of Cancer Using Proteomics Technology
Current Cancer Therapy Reviews The Klf6 Super-enhancer Determines Klf6 Sensitivity to BRD4 Inhibitors in Human Hepatoma (HepG2) Cells
Current Biotechnology Synthesis, DNA Binding Ability and Anticancer Activity of 2-heteroaryl Substituted Benzimidazoles Linked Pyrrolo[2,1-c][1,4]benzodiazepine Conjugates
Medicinal Chemistry Pluripotency and Targeted Reprogramming: Strategies, Disease Modeling and Drug Screening
Current Drug Delivery Telomere Maintenance as Therapeutic Target in Embryonal Tumours
Anti-Cancer Agents in Medicinal Chemistry Interaction and Reaction of the Antioxidant Mn<sup>III</sup> [Meso-Tetrakis(4-NMethyI Pyridinium) Porphyrin] with the Apoptosis Reporter Lipid Phosphatidylserine
Current Physical Chemistry Tetrapyrrolic Macrocycles: Potentialities in Medical Imaging Technologies
Current Organic Synthesis Novel Insights into Targeting ATP-Binding Cassette Transporters for Antitumor Therapy
Current Medicinal Chemistry